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ABSTRACT 
Hereditary sensory and autonomic neuropathy type IV (HSAN IV) is an autosomal recessive 
disorder characterized by a complete lack of pain perception and anhidrosis. Here, we studied 
a cohort of seven patients with HSAN IV and describe a comprehensive functional analysis 
of seven novel NTRK1 missense mutations, c.1550G>A, c.1565G>A, c.1970T>C, 
c.2096T>C, c.2254T>A, c.2288G>C, c.2311C>T, corresponding to p.G517E, p.G522E, 
p.L657P, p.I699T, p.C752S, p.C763S and p.R771C, all of which were predicted pathogenic 
by in-silico analysis. The results allowed us to assess the pathogenicity of each mutation and 
to gain novel insights into TRKA downstream signalling. Each mutation was systematically 
analyzed for TRKA glycosylation states, intracellular and cell membrane expression patterns, 
nerve growth factor stimulated TRKA autophosphorylation, TRKA-Y496 phosphorylation, 
PLCγ activity and neurite outgrowth. We showed a diverse range of functional effects: one 
mutation appeared fully functional, another had partial activity in all assays, one mutation 
affected only the PLCγ pathway and four mutations were proved null in all assays. Thus, we 
conclude that complete abolition of TRKA kinase activity is not the only pathogenic 
mechanism underlying HSAN IV. By corollary, the assessment of the clinical pathogenicity 
of HSAN IV mutations is more complex than initially predicted and requires a multifaceted 
approach. 
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INTRODUCTION 
Pain is a physiological protective mechanism that is essential for the detection and prevention 
of contact with noxious stimuli present in all multicellular organisms (Dubin and Patapoutian, 
2010). Such noxious stimuli are detected by specialized sensory neurons called nociceptors. 
During development, specification towards a nociceptive phenotype relies on the expression 
of the receptor called tropomyosin receptor kinase A (TRKA) for the final transition from 
mitotic precursor to post-mitotic nociceptor (Marmigere and Ernfors, 2007). Further 
underlining importance of TRKA in human pain, is that either its deficiency or deficiency of 
its ligand, nerve growth factor (NGF), results in an inherited form of congenital painlessness 
named Hereditary Sensory and Autonomic Neuropathy type IV (HSAN IV) and HSAN V 
respectively. In addition, novel antagonists or therapeutic antibodies against NGF-TRKA 
signalling are showing considerable promise as analgesics in clinical trials (Bannwarth and 
Kostine, 2014; Spierings et al. 2014). 
The human TRKA protein is encoded by the gene NTRK1 (MIM# 191315) located on 
chromosome 1q21-q22 (Figure 1A). The first isoform of NTRK1 includes all exons and yields 
a 796 residue protein that is predominantly expressed in neuronal tissues and provides 
responsiveness to both NGF and neurotrophin 3 (Barker et al. 1993). Exclusion of exon 9 in 
the second isoform results in a 790 residue protein that is primarily expressed in non-neuronal 
tissues and binds NGF alone (Barker et al. 1993). Previous studies have shown TRKA to be 
synthesized as an 87 kDa protein, which is immediately glycosylated to a 110 kDa form. 
Further glycosylation events occur to produce the mature and functional 140 kDa 
glycoprotein (Martin-Zanca et al. 1989), which is then trafficked to the plasma membrane 
(Watson et al. 1999).  
The TRKA receptor contains a single transmembrane domain that lies between the 
extracellular and intracellular domains. The extracellular domain consists of a number of 
structural motifs (Figure 1B) which specifies binding to NGF, whereas the majority of the 
intracellular domain comprises a tyrosine kinase domain (Huang and Reichardt, 2003). 
Intracellular signalling by TRKA is initiated by engagement with an extracellular NGF 
dimer, which causes the dimerization of two TRKA molecules (Figure 1C) and 
autophosphorylation of the TRKA kinase domain tyrosine residuesY676, Y680 and Y681 
(Cunningham et al. 1997). The subsequent structural change allows binding to ATP and 
results in phosphorylation of Y496 and Y791 (Cunningham and Greene, 1998; Artim et al. 
2012), which then act as adaptor sites for the downstream signalling molecules Shc and PLCγ 
respectively, summarized in Figure 1C. 
Recruitment of Shc (Dikic et al. 1995) and associated adaptor proteins to phosphorylated 
Y496, activates PI3K to promote neuronal survival (Datta et al. 1999; Yuang and Yanker, 
2000). Binding of other associated adaptor proteins to Shc activates the Ras/MAPK pathway 
(Dikic et al. 1995; MacDonald et al. 2000) (Figure 1C). PLCγ bound to phosphorylated Y791 
results in an increase in Ca2+ levels and activation of Ca2+/calmodulin-regulated protein 
kinases (Obermeier et al. 1993). The Ras/MAPK and PLCγ pathways converge to lead to 
transcription of genes that specifically drive neuronal differentiation (Riccio et al. 1999; 
Lonze et al. 2002). 
HSAN IV (OMIM #256800) is a rare autosomal recessive disorder that is caused by a failure 
of nociceptive and sympathetic neuron development. One of the characteristic features of 
HSAN IV is a congenital and complete insensitivity to both superficial and deep painful 
stimuli. Patients are prone to oral injuries as well as multiple accidental injuries such as 
burns, falls, and bone and joint fractures (Amano et al. 1998; Bar-On et al. 2002). Further 
key features of HSAN IV are a deficit of temperature sensing (Ismail et al. 1998; Axelrod 
2002) and developmental delay which becomes apparent within the first decade (Rosemberg 
et al. 1994). Recently it has been shown that lack of TRKA signalling increases the 
susceptibility of patients to infections, in particular to Staphylococcus aureus, through a 
monocyte/macrophage-specific NGF/TRKA pathway (Beiglman et al. 2009; Hepburn et al. 
2014). 
Many different mutations have been identified in HSAN IV patients, mostly nonsense 
mutations, but also missense, small insertions, small deletions and splicing variants. Only a 
small number of missense mutations have previously been functionally analyzed (review of 
information in Supp. Table S1), the mutations p.G516R, p.G571R, p.R643W, p.R648C, 
p.G708S and p.R774P (numbering based on RefSeq ID NP_001012331. All showed 
diminished kinase activity and absent autophosphorylation (Greco et al 1999; Greco et al. 
2000; Mardy et al. 2001; Miranda et al. 2002), and in addition, the extracellular domain 
mutations p.L93P and p.L213P were aberrantly processed and showed reduced kinase 
activity (Mardy et al. 2001; Miranda et al. 2002). 
We have identified seven novel missense mutations in NTRK1 from patients with HSAN IV. 
Extensive functional analysis of each mutation revealed a diverse and novel range of results 
and suggests multiple pathogenic mechanisms underlie HSAN IV. 
  
METHODS 
Molecular genetics, sequencing and segregation studies. 
The seven missense mutations described in this study were sequentially ascertained through 
an NHS genetics service. Patients were accepted for analysis if they had the minimal clinical 
characteristics of both a congenital pain insensitivity and cognitive delay. Sequencing was by 
standard Sanger analysis of each exon of NTRK1 (RefSeq ID NM_002529.3) using a 
customized set of primers designed to work under identical polymerase chain reaction 
conditions (primer sequences are available on request). The NGF gene (RefSeq ID 
NM_002506.2) was also sequenced using a set of primers designed to work under identical 
conditions.  
The conservation of the mutated residues was analyzed using the multiple sequence 
alignment tool Clustl Omega version 1.2.2 (McWilliam et al. 2011) 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). Pathogenicity of mutations was predicted by 
PolyPhen-2 (Adzhubei et al. 2010) (http://genetics.bwh.harvard.edu/pph2/) and by SIFT 
(Kumar et al. 2009) (http://sift.jcvi.org/www/SIFT_enst_submit.html). For all tools, default 
settings were used. Our chromosome and mutation lab results have been uploaded on 
DECIPHER (https://decipher.sanger.ac.uk), where they are freely available, under an 
agreement with NHS-CAM and also on LOVD database 
(http://grenada.lumc.nl/LSDB_list/lsdbs/NTRK1).  
Cloning of expression constructs 
The construct for wild-type full length TRKA was obtained from IMAGE clones (Source 
BioSciences). A C-terminal GFP tagged TRKA construct was generated by introducing full 
length NTRK1 cDNA into the pEGFP-N1 cloning vector (Clontech) as described previously 
(Mitchell et al. 2012), and henceforth referred to as wild-type TRKA-GFP. GFP tagged 
TRKA had a similar activity to untagged TRKA (Supp. Figure S1). All the point mutations 
were introduced using the QuikChange II Site-directed Mutagenesis Kit (Agilent 
Technologies). 
Cell culture and conditions 
HEK-293, HeLa, and SH-SY5Y cells were cultured in complete DMEM supplemented with 
10% FBS, 2 mM L-glutamine and 100 µg/ml penicillin and 100 µg/ml streptomycin, at 37 oC 
and 5% CO2. 
For localization studies, HEK-293 cells were plated on poly-L-lysine coated coverslips at a 
seeding concentration of 1x105 cells/ml. For neurite outgrowth SH-SY5Y cells were plated 
on poly-L-lysine coated coverslips at 5x104 cells/ml. Cells were transiently transfected with 
500 ng DNA with Fugene HD transfection reagent (Promega). 
For glycosylation assessment, HEK-293 cells were plated at a seeding concentration 2.5 x105 
cells/ml. For phospho-ELISA assays and calcium imaging, HeLa cells were plated at 
1.25x105 cells/ml. For calcium imaging cells were plated on poly-L-lysine coated 35 mm 
glass bottom dishes. In all cases cells were transiently transfected with 2.5 µg DNA using 
Fugene HD for 24 h. 
Colocalization analysis 
24 h post-transfection, HEK-293 cells were washed in phosphate buffered saline (PBS) and 
fixed in ice-cold methanol. Cells were stained with GFP antibody (Abcam, ab6556, 1:1000) 
and Na+/K+ ATPase α1 subunit antibody (Abcam, ab7671, 1:300) . Alexa-488 and Alexa-546 
conjugated secondary antibodies were purchased from Invitrogen (1:1000). All images were 
acquired with an LSM710 laser-scanning META confocal microscope (Carl Zeiss) using a 
x63 oil-immersion objective. 
Image analysis was performed using the Volocity image analysis software (PerkinElmer). 
Colocalization was quantified in terms of Manders M1 coefficient. The proportion of GFP at 
the membrane was quantified by measuring the GFP at the plasma membrane and dividing by 
the total GFP fluorescence. 
Glycosylation assessment 
Transfected HEK-293 cells were washed with 1x PBS and scraped in RIPA buffer (Tris pH 
7.4, NaCl 150 mM, EDTA, 0.5 mM, 1% Triton ), containing protease inhibitors (Roche 
Applied Sciences). Lysates were cleared by centrifugation at 16 000 g at 4 oC for 25 minutes 
and levels of total cellular protein tested using the DC protein assay kit (BioRad). 25 µg of 
total protein was treated with PNGase (NEB) following manufacturer’s protocol or was left 
untreated.  
PNGase treated and untreated protein lysate were separated using 6% Tris-glycine gels 
(Invitrogen) and transferred to PVDF membrane (Millipore). Blots were then probed with 
GFP (D5.1) XP Rabbit mAb #2956 (Cell Signaling Technologies, 1:1000) and lamin 
antibody (Abcam, ab133741, 1:1000). Secondary antibodies were purchased from Dako and 
signal was detected using the chemiluminescent HRP substrate (Millipore). Densitometry 
was performed with ImageJ software (NIH). 
Phospho-TRKA assays 
24 h post transfection, HeLa cells were serum starved in DMEM supplemented with 1% FBS 
at 37 oC for 1 h. Cells were then treated with 100 ng/ml NGF (CST) for 5 min at 37 oC or 
were left untreated and washed in 1x tris buffered saline. Lysate was collected as mentioned 
previously, with one alteration: RIPA buffer was supplemented with a 1:100 dilution of 
phosphatase inhibitor cocktails 2 and 3 (Sigma). 
The autophosphorylation and Y496 phosphorylation levels were determined using the 
PathScan® Phospho-TRKA Sandwich ELISA 674/675 Kit (CST) and PathScan® Phospho-
TRKA Tyr490 Sandwich ELISA kit (CST) respectively, following manufacturer’s protocol. 
Total TRKA levels in the lysates were also measured using PathScan® Total TRKA 
Sandwich ELISA kit (CST). 
The relative levels of phosphorylated TRKA were calculated by dividing phosphorylated 
values by total TRKA values. This was then normalized to the relative phosphorylation of 
wild-type transfected cells without NGF treatment. 
Calcium imaging 
24 h post-transfection, calcium imaging was performed on HeLa cells using Rhod-3-AM 
calcium imaging kit (Invitrogen) following manufacturer’s protocol. Images were acquired 
with an LSM710 laser scanning META confocal microscope (Carl Zeiss) using a x20 
objective and maximum pinhole aperture of 600 μm. Two line averages were performed for 
each frame with images taken every 4 s.  
At t= 48 s, 20 μl of HBSS media was added, at t= 140 s, 20 μl NGF (final concentration of 
100 ng/ml) was added to the cells. The response to NGF was monitored for 10 min, after 
which at t= 820 s, 100 ng/ml ionomycin was added. For PLCγ inhibition studies, WT 
transfected cells were treated with 3 µg/ml of U73122 (Calbiochem) for 30 min prior to NGF 
stimulation. 
Image analysis was performed with the Volocity 3D Image Analysis Software using green 
cells that did not spontaneously fluoresce and had an ionomycin response. 
Neurite outgrowth assays 
24 h post transfection, SH-SY5Y cells were treated with 100 ng/ml NGF in DMEM 
supplemented with 5% FBS for 9 days, with media being replaced every 3 days. Cells were 
then washed in PBS and fixed in 4% paraformaldehyde and were imaged with an LSM510 
laser scanning META confocal microscope (Carl Zeiss) using a x40 immersion oil objective. 
Cells were analyzed using the ImageJ software. A neurite was identified as being more than 
twice the cell body length, where the longest dimension was used (Nahorski et al. 2015). 
Total neurite length per cell was also quantified where all extensions were measured and 
divided by the total number of cells counted (Nahorski et al. 2015).  
Structural modelling 
The homology model of the human TRKA tyrosine kinase domain (UniProtKB: P04629) was 
created using in-house Pfizer software and Modeler 9v8 (http://salilab.org/modeller/) (Sali 
and Blundell, 1993) using human TRKA structures 4AOJ_A, 4GT5, 4PM, 4PP, 4PS and 
4PT, deposited in the Protein Data Bank as templates, 
http://www.rcsb.org/pdb/home/home.do, as previously described (Veale et al. 2014). 
Statistical analysis 
The data show the mean ± standard error of the mean (SEM). Statistical significance was 
calculated using a one-way ANOVA, followed by unpaired, two sided Student’s t-test using a 
Bonferroni corrected adjusted P-value. Significance was set at *P<0.05, **P<0.01 or 
***P<0.001. 
  
RESULTS 
Putative mutations in NTRK1 
Seven cases with a typical HSAN IV phenotype, in which parents had no features of HSAN 
IV, were referred to the East Anglian NHS Genetics Services for HSAN IV analysis and were 
sequentially identified. The probands ages were from 3 to 15 years. They had no evidence of 
having pain or temperature perception, had cognitive global delay ranging from mild to 
moderate. They did not sweat and usually had icthyotic areas of skin with troublesome 
puritis. Those over 10 years of age had evidence of Charcot’s joints in the lower limbs, and 
had had at least one significant episode of S. aureus infection. (For full clinical and mutation 
details, see Supp. Table S2.) Four cases were consanguineous, whilst three cases were from 
singleton families. Through sequencing analysis, we found three individuals who were 
homozygous for different NTRK1 mutations, two cases with a heterozygous missense 
mutation and a heterozygous nonsense mutation and one case with two heterozygous 
missense mutations. Sequencing of both parents in all cases confirmed that the mutations 
segregated as expected for an autosomal recessive disorder. NGF was also sequenced and 
contained no mutations. The novel identified mutations were c.1550G>A, c.1565G>A, 
c.1970T>C, c.2096T>C, c.2254T>A, c.2288G>C, c.2311C>T (RefSeq ID NM_002529.3), 
corresponding to the TRKA protein changes p.G517E, p.G522E, p.L657P, p.I699T, p.C752S, 
p.C763S and p.R771C respectively (Figure 1D and Supp. Figure S2). Nucleotide numbering 
uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the 
initiation codon as codon 1. There are no variations at these positions recorded in the 1000 
Genomes Server, dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), the Exome Variant Server 
(http://evs.gs.washington.edu/EVS/) or the ExAC database (http://exac.broadinstitute.org). 
p.G522R (called p.G516R in the paper) has previously been reported in a HSAN IV case 
(Mardy et al. 2001). Interestingly, all of the mutations identified here were located 
intracellularly within the kinase domain ( Supp. Figure S2 and Supp. Figure S3), as is the 
case for most of the previously described missense mutations in NTRK1. All mutations were 
in evolutionarily conserved residues and were predicted to be pathogenic by Polyphen and 
SIFT (Supp. Figure S3). As none of the mutations would be expected to cause a loss of or 
instability of the TRKA protein, a number of different studies were undertaken to determine 
the pathogenic mechanism. Table 1 summarizes the results. 
Glycosylation changes in TRKA mutants 
We first determined whether the mutations affected protein synthesis or post-translational 
modification. C-terminal tagged GFP wild-type and mutant constructs were transfected into 
HEK-293 cells and lysates were collected and were either treated with peptide-N-glycosidase 
(PNGase) or were left untreated. PNGase treatment of wild-type and mutant lysate removed 
N-glycosylation to yield an unglycosylated backbone of 117 kDa (Figure 2A). Untreated 
lysate of wild-type TRKA-GFP had two protein bands: the fully glycosylated 170 kDa 
product and the partially glycosylated 140 kDa product. All of the mutants clearly showed the 
170 kDa fully glycosylated and 140 kDa partially glycosylated products. However, compared 
to wild-type TRKA-GFP, p.L657P showed a 4-fold reduction in the fully glycosylated form, 
whilst p.I699T and p.R771C showed a 2.5-fold reduction (**P<0.01, Figure 2B). p.C763S 
also showed a 1.3-fold reduction in the 170 kDa form (*P<0.05, Figure 2B). p.G517E, 
p.G522E and p.C752S showed a glycosylation pattern that was similar to wild-type TRKA-
GFP. 
Localization of TRKA-GFP mutant proteins 
We then determined the localization of the mutant TRKA-GFP proteins to see whether the 
glycosylation changes observed affected the subcellular localization. HEK-293 cells were 
transfected with wild-type and mutant constructs and were stained with antibodies against 
GFP, shown in green, and the plasma membrane marker Na+/K+ ATPase α1 subunit, shown 
in red (Figure 2C). As previously observed, wild-type TRKA-GFP was present around the 
periphery of the cells and colocalized with Na+/K+ ATPase staining (Supp. Figure S4). 
Staining of wild-type TRKA-GFP demonstrated that 45% of the protein was located at the 
cell surface with the remainder being located intracellularly (Figure 2D). This was not 
significantly different in cells expressing the p.G517E, p.G522E or p.C752S mutations. 
Although the remaining mutant proteins colocalized at the plasma membrane, the proportion 
of GFP at the membrane was significantly reduced to approximately 20% to that of wild-type 
TRKA-GFP (Figure 2D).  
Although many of the mutations altered the glycosylation status of TRKA-GFP and its 
localization, they did not completely block trafficking of the receptors to the plasma 
membrane. Therefore, we next questioned whether the mutants could activate various 
downstream signalling pathways. 
Autophosphorylation of TRKA-GFP mutant proteins 
We next looked at the effects of the mutations on autophosphorylation of TRKA-GFP. HeLa 
cells were transfected with wild-type and mutant constructs. The basal level of 
autophosphorylation of wild-type TRKA-GFP increased 2.5 fold after NGF stimulation 
(Figure 3A). There was a 3-fold reduction in basal levels of autophosphorylation in four of 
the mutants, namely p.G522E, p.L657P, p.I699T and p.R771C (***P<0.001) and there was 
no induction of NGF-stimulated TRKA-GFP autophosphorylation (***P<0.001, Figure 3A). 
There were no observable differences in the basal levels of autophosphorylation, nor 
induction of autophosphorylation after NGF stimulation in p.G517E and p.C752S. In 
p.C763S there was a 3-fold reduction in basal levels of autophosphorylation and NGF 
stimulated autophosphorylation (**P<0.01).  
Y496 phosphorylation of mutant TRKA-GFP proteins 
We then looked at the effect of the mutations on Y496 phosphorylation which is important 
for the recruitment of Shc and downstream signalling through PI3K and the Ras/MAPK 
pathway. HeLa cells were transfected with wild-type and mutant constructs, and then NGF 
stimulated. The basal level of wild-type TRKA-GFP Y496 phosphorylation increased 3-fold 
upon NGF stimulation (Figure 3B). The four mutants, p.G522E, p.L657P, p.I699T and 
p.R771C, which showed defective autophosphorylation, did not induce Y496 
phosphorylation after NGF stimulation (***P<0.001), whereas p.G517E and p.C752S did not 
alter basal nor NGF-stimulated Y496 phosphorylation. In p.C763S there was a 3-fold 
reduction in basal Y496 phosphorylation and a 2.5-fold reduction in NGF-stimulated Y496 
phosphorylation (**P<0.01).  
Induction of PLCγ pathway 
As p.G517E and p.C752S did not seem to have any effect upon trafficking or 
autophosphorylation, as described above, we determined their ability to activate the PLCγ 
pathway through monitoring calcium flux after NGF stimulation. We also tested the other 
mutants. HeLa cells were transfected and loaded with the calcium indicator dye rhodamine-3. 
In wild-type transfected cells, after NGF stimulation, there was an increase in basal 
fluorescence (Figure 4A) to a maximum fluorescence of 2.5 AU at t = 208s (Supp. Figure 
S5A). Furthermore, 90% of transfected cells responded to NGF (Supp. Figure S5B). 
Treatment with U73122, a PLCγ inhibitor, abolished induction of NGF increase of calcium 
(Supp. Figure S5C).  
Fluorescence remained at basal levels in cells transfected with the mutant proteins that did 
not autophosphorylate or phosphorylate Y496 (Supp. Figure S5A). NGF stimulation of 
p.G517E transfected cells did not induce an increase in red fluorescence (Figure 4B), which 
remained at basal levels (**P<0.01) and the percentage of cells responsive to NGF was 3% 
(Supp. Figure S5B). There was no observable difference in the calcium response in p.C752S 
transfected cells (Figure 4C) compared to the response observed in wild-type TRKA-GFP 
proteins. In p.C763S transfected cells, basal fluorescence increased to a maximum value of 
1.2 AU (Figure 4D, **P<0.01) and only 50% of cells were NGF responsive.  
Neurite outgrowth 
Activation of the different signalling pathways triggered by TRKA ultimately results in 
differentiation towards a neuronal phenotype (Huang and Reichardt, 2003). Consequently, we 
looked at the effect of selected mutations on induction of neuronal differentiation. The 
neuroblastoma cell line SH-SY5Y was transfected with wild-type TRKA-GFP, the mutants 
p.G517E, p.L657P, p.C752S, p.C763S and empty vector and treated with NGF over nine 
days (Figure 5A). 
After nine days of NGF stimulation, 40% of cells transfected with wild-type TRKA-GFP 
differentiated into a neuronal phenotype (Figure 5B) and the average neurite length was 360 
AU (Figure 5C). Although there was a significant reduction in the percentage of 
differentiated p.G517E transfected cells (***P<0.001), the average neurite length was not 
significantly different. p.C752S did not affect neurite outgrowth nor neurite length. The 
p.C763S mutation resulted in a significant reduction in the percentage of differentiated cells 
to 20% (***P<0.001) and a significant reduction of neurite length (***P<0.001). p.L657P 
was included as a negative control and only 5% of transfected cells could be classified as 
differentiated, which resembles the percentage of spontaneous differentiated cells in the 
empty transfected control.  
Structural modelling of TRKA mutations 
We next modelled the structural consequences of the mutations on the kinase domain (Supp. 
Figure S2, Supp. Figure S3C). We found that p.G517 and p.G522 are the first and third 
glycine residues within the ATP binding domain GxGxxG. Ligand binding and 
autophosphorylation of TRKA induce a conformational change that shifts TRKA into an 
open conformation and allows binding of ATP which increases the kinase activity (Jullien et 
al. 2002). p.L657 is structurally within the active site of TRKA, where it is likely to have a 
stabilization role. p.I699 is within the activation loop, which is essential for 
autophosphorylation and hence may have a role in enabling autophosphorylation to occur. 
p.C752, p.C763 and p.R771 are all within the catalytic domain of TRKA and hence are likely 
to affect activity of TRKA. 
 
  
DISCUSSION 
In this study we report seven novel missense mutations found in patients with a HSAN IV 
phenotype. We have undertaken a comprehensive assessment of the effects of each of these 
mutations on TRKA function, using a greater range of methods than has been previously 
reported (Greco et al. 1999; Greco et al. 2000; Mardy et al. 2001; Miranda et al. 2002): 
glycosylation and membrane expression, autophosphorylation, Y496 phosphorylation, PLCγ 
activation and effects on neurite outgrowth (summarized in Table 1).  
Glycosylation of TRKA is essential for its function and thus we assayed this for each of our 
mutations. p.G517E showed a similar glycosylation pattern to wild-type TRKA-GFP. We 
observed no changes in subcellular localization for this mutant protein as full glycosylation is 
required for trafficking to the plasma membrane (Watson et al 1999). p.G517E did not affect 
autophosphorylation and as a result downstream phosphorylation of Y496 was found to be 
unaffected. However, the p.G517E mutation completely abolished PLCγ signalling and we 
found that the mutation was less efficient at promoting differentiation and neurite outgrowth. 
p.G517E is the first glycine in the ATP binding domain GxGxxG. Hence it is surprising that 
Y496 phosphorylation is observed and PLCγ signalling is abolished. The attenuation of PLCγ 
signalling may be due a conformational change within the kinase domain that alters PLCγ 
signalling. This is the first mutation identified within the kinase domain that does not alter 
kinase activity of TRKA. It is also the first mutation identified to date that only affects one 
signalling pathway and yet is sufficient to restrict differentiation and thus must be the 
pathogenic mechanism behind HSAN IV. The result highlights the fact that when assessing 
the pathogenicity of TRKA patient mutations, it is not sufficient to just look at 
autophosphorylation or Y496 phosphorylation as has been done previously (Greco et al 1999; 
Greco et al. 2000; Mardy et al. 2001; Miranda et al. 2002). Clinically the patient with 
p,G517E mutation had typical HSAN IV phenotype and was indistinguishable from our other 
cases.  
p.G522E mutation also showed a similar glycosylation pattern to wild-type TRKA and hence 
no differences in membrane expression were observed. There was no induction of TRKA 
autophosphorylation after NGF stimulation. As a consequence of a lack of TRKA activation, 
downstream signalling through Y496 and PLCγ were abolished. As this mutant protein 
retains membrane localisation, it is likely that the primary pathogenic mechanism is absent 
intrinsic kinase activity. The effect of this mutation is unexpected because p.G522E resides 
within the ATP binding domain and autophosphorylation is not dependent on ATP binding. 
Hence it appears that G522 may function directly in kinase activity and changes to the 
structure of the kinase domain leads to no kinase function. This is confirmed by studies on a 
different mutation at this site, p.G522R (termed p.G516R in the paper) where the mutation 
also rendered the protein kinase-dead (Mardy et al. 2001). 
p.L657P, p.I699T, and p.R771C all exhibited similar results in the assays performed. We 
found a decrease of fully glycosylated TRKA-GFP in these mutant proteins and the partially 
glycosylated 140 kDa product was favoured. We hypothesized this effect may be explained 
by mutation-induced conformational changes that alter the accessibility of enzymes to the 
glycosylation sites. An alternative explanation could be that these mutations cause aberrant 
folding of the TRKA kinase domain, that may be detected by cellular proofing systems and 
start degrading these mutants even before they become fully glycosylated. Furthermore, these 
mutations had more TRKA-GFP protein in the cytoplasm than at the plasma membrane, 
confirming previous results that trafficking to the plasma membrane is related to 
glycosylation status. However, as there was some TRKA-GFP at the membrane for each of 
these mutations, we next sought to investigate downstream signalling pathways. In all cases 
TRKA-GFP autophosphorylation was abolished. Neurite outgrowth in p.L657P (as a 
representative) was also abolished. As the four kinase-dead mutants retained some membrane 
localization it is likely that the primary pathogenic mechanism is absent intrinsic kinase 
activity. Structural modelling showed that p.G522E, p.L657P, p.I699T and p.R771C were 
located in important parts of the kinase domain: the ATP binding domain, active site, 
activation loop and the catalytic domain respectively. It is likely that the mutations introduce 
a change to the 3D structure of the kinase domain which would lead to a lack of kinase 
activity. As such, it is unsurprising that autophosphorylation is affected and our results 
confirm that these residues have an essential role in autophosphorylation. These results are 
similar to those published previously where most the missense mutations were found to 
produce kinase-dead mutants (Greco et al 1999; Greco et al. 2000; Mardy et al. 2001; 
Miranda et al. 2002).  
C752S did not affect glycosylation and hence did not affect trafficking to the membrane. In 
addition, autophosphorylation, Y496 phosphorylation and PLCγ activation were unaffected. 
Furthermore, neurite outgrowth data indicated that the mutation did not affect differentiation. 
p.C752S is within the catalytic domain but we could find no evidence of disrupted function. 
This heterozygous mutation was found in-trans with the heterozygous kinase-dead p.G522E 
mutation and no other NTRK1 change was detected despite complete Sanger sequencing. 
Furthermore, the nucleotide change was not predicted to change or create a splice site. Thus it 
appears that even though this mutation affects an evolutionary conserved residue, it is not 
pathogenic and in fact could be a rare but harmless polymorphism. In this family we have 
failed to discover the other pathogenic mutation in NTRK1. The C752S result highlights the 
weakness of in silico predictions of pathogenicity and indicates functional work is necessary 
to call for pathogenic mutations.  
p.C763S is within the catalytic domain and only partially reduced both autophosphorylation 
and consequently Y496 phosphorylation. Nonetheless this is sufficient to cause disease. This 
suggests that there is an essential level of activation of TRKA required before nociceptor 
differentiation can take place. As we found this patient to be phenotypically indistinguishable 
from our other HSAN IV cases, it must be concluded that the mutations renders the TRKA 
signal insufficient to trigger differentiation. This is the first reported case where a reduction 
in TRKA signalling, but not abolition, leads to a HSAN IV phenotype. 
In conclusion, we report seven novel NTRK1 mutations in individuals with a diagnosis of 
HSAN IV, and have found evidence to support pathogenicity in six. Our results highlight the 
fact that when assessing the pathogenicity of TRKA mutations (for example p.G517E), it is 
not sufficient to only assess autophosphorylation or Y496 phosphorylation, as has been done 
previously (Greco et al 1999; Greco et al. 2000; Mardy et al. 2001; Miranda et al. 2002). 
Similarly complete evolutionary conservation is also not an absolute predictor of 
pathogenicity, as we found no evidence that p.C752S was pathogenic, confirming the need 
for caution when interpreting the pathogenicity of unknown variants (Waxman et al. 2014). 
Our data highlights the complexity of TRKA function and suggests that perturbation of any 
part of the downstream signalling may lead to a loss of nociceptor development. 
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LEGENDS TO FIGURES 
Figure 1: TRKA structure, signalling and Identification of novel NTRK1 mutations in 
patients with HSAN IV 
(A): NTRK1 located on chromosome 1q21-q22, shown by the grey bar on the 
ideogram, consists of 17 exons and spans region of 25 kb. Inclusion of all 17 exons 
encodes for the neuronal specific isoform of TRKA.  
(B): The extracellular domain of TRKA consists of a number of structural domains: a 
leucine rich repeat, flanked on either side by a cysteine rich domain, and two 
immunoglobulin-like domains. The majority of the intracellular domain comprises the 
kinase domain. 
(C): Signalling through TRKA is initiated through NGF binding, TRKA dimerization, 
and autophosphorylation of Y676, Y680 and Y681. Subsequent phosphorylation of 
Y496 and Y791 leads to activation of downstream signalling cascades which drive 
neuronal differentiation and survival.  
(D): Seven individuals were ascertained with a standard HSAN IV phenotype. The 
identified mutations were p.G517E, p.G522E, p.L657P, p.I699T, p.C752S, p.C763S 
and p.R771C. Only the exons that code for the kinase domain are shown. TKD: 
tyrosine kinase domain. 
  
Figure 2: Expression, processing and localization of wild-type and mutant TRKA 
(A): Expression of C-terminal GFP tagged wild-type and mutant TRKA constructs in 
transfected HEK-293 cells. The lanes “+” and “-” represent lysates treated 
with/without PNGase respectively. Lamin B1 was included as a loading control. 
Representative image of n= 3 is shown. WT: wild-type, EV: empty vector. 
(B): Quantification of relative levels of fully glycosylated 170 kDa TRKA-GFP 
protein to the levels of partially glycosylated 130 kDa TRKA-GFP protein.  
(C): Localization of TRKA-GFP wild-type and mutant proteins in transfected HEK-
293 cells. The cells were stained against GFP (green) and the plasma membrane 
marker Na+/K+ ATPase (red). Wild-type TRKA and all the mutants show membrane 
expression. 
(D): Relative levels of GFP at the membrane compared to the levels of GFP in the 
cytoplasm. Graph represents mean values of n= 3, with at least 15 cells in each repeat, 
and error bars represent standard error of the mean. 
Statistical differences are indicated as *P<0.05, **P<0.01 (one-way ANOVA, 
followed by Student’s t test using a Bonferroni adjusted P-value). 
Figure 3: Relative Y680/681 and Y496 phosphorylation of mutant TRKA 
(A): Basal level of wild-type and mutant TRKA-GFP autophosphorylation in 
transfected untreated HeLa cells. Response to wild-type and mutant TRKA-GFP 
protein to 15 min stimulation with 100 ng/ml NGF.  
(B): Basal level of Y496 phosphorylation in wild-type and mutant TRKA proteins in 
untreated cells and after NGF stimulation.  
The bar graphs in A and B represents the mean values of n= 3 and error bars 
represents standard error of the mean. Statistical differences between induced 
phosphorylation of wild-type and mutant TRKA are indicated as **P<0.01 or 
***P<0.001 (one-way ANOVA, followed by Student’s t test using a Bonferroni 
adjusted P-value). WT: wild-type; EV: empty vector 
Figure 4: Effect of mutations on induction of PLCγ pathway 
(A): HeLa cells were transfected with wild-type and mutant TRKA constructs and 
loaded with rhodamine-3 and response to NGF was monitored. Ionomycin was used 
as the positive control. Only cells that did not spontaneously fluoresce and had an 
ionomycin response were used for analysis. WT: wild-type. 
(B): No significant increase in calcium levels was observed after NGF stimulation in 
p.G517E transfected cells.  
(C): There was an increase in fluorescence in p.C752S transfected cells which peaked 
at t= 208.  
(D): NGF stimulation on cells transfected with p.C763S caused an increase in 
fluorescence but the maximum value was reduced. 
Figure 5: Differentiation ability of selected mutants 
(A): Representative images of transfected SH-SY5Y cells treated with NGF for 9 
days. WT: wild-type, EV: empty vector. Green signal indicates transfected cells, blue 
DAPI nuclear stain. 
(B): Quantification of percentage of neurite bearing cells. A neurite was defined as 
being two times the cell body length.  
(C): Average neurite length was also quantified. For this all extensions however small 
were measured. 
The bar graphs in B and C represent the mean values of n= 3, with 60 cells in each 
repeat, and error bars represent standard error of the mean. Statistical differences are 
indicated as **P<0.01 or ***P<0.001 (one-way ANOVA, followed by Student’s t test 
using a Bonferroni adjusted P-value). 
 
B 
A 
C 
  AKT/PKB 
Neuronal survival 
MAPK cascade 
Neurite outgrowth 
  PKC Ca2+ 
PLCγ 
Plasma membrane 
TRKA 
Y791 
Y680 
Y681 
Y496 
  NGF   NGF 
  Grb   Sos     PI3K Shc P   Grb   Gab   PI3K Shc P 
P 
P 
P 
Ras 
SP Cys Cys LRR IgC1 IgC2 TM TKD 
Gene 
Protein 
                                                                                          1                               2                              3                                                                  4                                                                                                                5                                                                                           6                                                      7                                                                     8                                                                                                                                                      9                                                      10                                                                                                          11                             12                                                                                       13                                                                                                                14                         15                                                                                                          16                                                                                                                          17 
Chr1 (q23.1) 
Gene 
Protein 
13                                                                                                                                         14                                                      15                                                                                                                                                 16                                                                                                                                                         17 
p.G517E   p.G522E                             p.L657P          p.I699T       p.C763S 
   p.C752S     p.R771C 
TKD 
D 
Key: 
SP: signal peptide 
Cys: cystein rich domain 
LRR: leucine rich repeat 
IgC: immunoglobulin-like domain 
TM: transmembrane domain 
TKD: tyrosine kinase domain 
00.4
0.8
1.2
1.6
R
e
la
ti
ve
 f
lu
o
re
sc
e
n
ce
 (
A
U
) 
 
0
0.4
0.8
1.2
1.6
R
e
la
ti
ve
 in
te
n
si
ty
 (
A
U
) 
*** 
*** 
*** *** 
D 
                  WT                                              p.G517E          
  p.C763S                   p.R771C  
                           p.I699T                                          p.C752S 
p.G522E                                          p.L657P 
C 
-          + -          + PNGase
GFP 
 
 
Lamin 
kDa 
250 
 
130 
 
95  
  
70  
-           + -          + -          + -          + -          + 
A 
B 
-          + -          + 
** 
** ** 
* 
0100
200
300
R
e
la
ti
ve
 p
h
o
sp
h
o
ry
la
ti
o
n
 (
%
) 
  -NGF
 +NGF
A 
**
* 
**
* 
**
* 
**
 
**
* 
0
100
200
300
R
e
la
ti
ve
 p
h
o
sp
h
o
ry
la
ti
o
n
 (
%
) 
 -NGF
 +NGF
B 
**
* 
**
* 
**
* 
**
 
**
* 
02
4
6
0 400 800 1200
R
e
la
ti
ve
 f
lu
o
re
sc
e
n
ce
 (
A
U
) 
 
10 µm 
      Pre-NGF application                              Post-NGF application                   Post-ionomycin application 
A 
B 
D 
0
2
4
6
0 400 800 1200
R
e
la
ti
ve
 f
lu
o
re
sc
e
n
ce
 (
A
U
) 
 
WT 
p.C752S 
0
2
4
6
0 400 800 1200
R
e
la
ti
ve
 f
lu
o
re
sc
e
n
ce
 (
A
U
) 
 
Time (s) 
p.C763S 
0
2
4
6
0 400 800 1200
R
e
la
ti
ve
 f
lu
o
re
sc
e
n
ce
 (
A
U
) 
 
p.G517E 
10 µm 
C 
10 µm 
10 µm 
10 µm 
0200
400
N
e
u
ri
te
 le
n
gt
h
 (
A
U
) 
A 
        p.C752S                                          p.C763S                                               EV 
                WT                                              p.G517E                                          p.L657P 
*** 
*** 
*** 
*** 
B 
C 
*** 
** 
*** 
0
20
40
P
e
rc
e
n
ta
ge
 (%
) 
00.5
1
1.5
2
Tagged Untagged Tagged Untagged
Y680/681 Y496
R
e
la
ti
ve
 a
b
so
rb
an
ce
 (
A
U
) 
 -NGF
 +NGF
A 
p.Gly522 p.Gly517 
p.Leu657 
p.IIe699 
p.Arg771 p.Cys763 
p.Cys752 
ATP 
A 
p.G517E          LKWEL EGAFG 
H. sapiens    LKWEL EGAFG 
X. laevis    LKREL EGAFG 
D. rerio    LKWEL EGAFG 
G. gallus    LKWEL EGAFG 
D. melanogaster  FLEEL EGAFG 
C. elegans   VREKI EGQFG 
p.C752S          ERPRA PPEVY 
H. sapiens    ERPRA PPEVY 
X. laevis        QRPRT PKEVY 
D. rerio    ERPRT PKEVH 
G. gallus    ERPRT PSEVY 
D. melanogaster  SAPEN PTAVY 
C. elegans    ECPHN PTNIY 
p.G522E          GEGAF KVFLA 
H. sapiens    GEGAF KVFLA 
X. laevis   GEGAF KVFLA 
D. rerio   GEGAF KVYLA 
G. gallus   GEGAF KVFLA 
D. melanogaster  GEGAF KVYkG 
C. elegans       GEGQF VVHSG 
p.C763S          AIMRG WQREP 
H. sapiens    AIMRG WQREP 
X. laevis    ALMRG WQREP 
D. rerio    LLMQG WQREP 
G. gallus    DIMQS WQREP 
D. melanogaster  SLMIE WHEQS 
C. elegans    SLMVE WHENI 
p.I699T          MPPES LYRKF 
H. sapiens    MPPES LYRKF 
X. laevis    MPPES MYRKF 
D. rerio    MPPES MYRKF 
G. gallus    MPPES LYRKF 
D. melanogaster  MPSES LYGKF 
C. elegans   MSKEA EQGRF 
p.L657P          ATRNC VGQGL 
H. sapiens    ATRNC VGQGL 
X. laevis    ATRNC VGENL 
D. rerio    ATRNC VGEGL 
G. gallus    ATRNC VGHDL 
D. melanogaster  AARNC VNEGL 
C. elegans       ATRNC VGDTR 
p.R771C          KDVHA LQALA 
H. sapiens    KDVHA LQALA 
X. laevis    KEIHS LQNLS 
D. rerio    KDIYS LVALV 
G. gallus        QDIHS LQALV 
D. melanogaster  TDISN LKTWH 
C. elegans   SEIRS LQSWS 
Mutation SIFT 
prediction  
score 
Polyphen 
prediction  
score 
p.G517E 0.00 1.000 
p.G522E 0.00 1.000 
p.L567P 0.00 0.983 
p.I699T 0.00 0.953 
p.C752S 0.00 1.000 
p.C763S 0.00 1.000 
p.R771C 0.00 1.000 
A 
B 
481 GKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGA 
521 FGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQRE 
561 AELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRF 
601 LRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVY 
641 LAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDY 
681 YRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEI 
721 FTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIM 
761 RGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG 
ATP binding domain 
Active site 
Activation loop 
Catalytic domain 
C 
00.2
0.4
0.6
0.8
1
M
1
 c
o
e
ff
ic
ie
n
t 
A 
025
50
75
100
P
e
rc
e
n
ta
ge
 (%
) 
*** 
0
1
2
3
Fl
u
o
re
sc
e
n
ce
 (A
U
) 
** ** ** ** 
** 
** ** 
A 
B 
C 
0
2
4
6
0 400 800 1200
R
e
la
ti
ve
 f
lu
o
re
sc
e
n
ce
 (
A
U
) 
*** *** *** *** *** 
** 
Supplementary Figure S1: Activity of GFP-tagged and untagged wild-type TRKA 
 
To test whether the introduction of GFP at the C-terminus of TRKA affected its function, we 
introduced the stop codon, TAG, into the construct using site directed mutagenesis and 
introduction of the mutation was confirmed by sequencing. HeLa cells were then transfected 
with the two different constructs, and were treated with NGF or were left untreated. 
Y680/681 autophosphorylation and Y496 phosphorylation were determined by ELISA. There 
was no observable differences in the basal levels of autophosphorylation or Y496 
phosphorylation in cells transfected with GFP-tagged and untagged constructs (P= 0.40, P= 
0.37, respectively, n= 3, Student’s t test). Furthermore, NGF-induced autophosphorylation 
and Y496 phosphorylation were not different in cells transfected with GFP-tagged and 
untagged constructs (P= 0.85, P= 0.90, respectively, n= 3, Student’s t test).  
  
Supplementary Figure S2: TrkA structure and position of mutated residues 
 
According to the structural model of the kinase domain of TRKA, p.G517, p.G522 
and p.L657, located in the ATP binding domain and the active site, are in close 
proximity to ATP. Any alteration to these residues is likely to interfere with 
interaction with ATP and may lead to structural alterations. p.I699 is located within 
the activation loop and the three remaining residues are within the catalytic domain 
and possibly are required for substrate binding. 
  
Supplementary Figure S3: Alignment and conservation of mutated residues  
 
(A): The missense TRKA candidate mutations all resulted in the change of an evolutionary 
conserved amino acid. Protein sequence data are for human as a representative mammal 
(TKRA, NP_00252), Xenopus laevis for amphibians (NP 001079579.1), Danio rerio for fish 
(NP_001288285), Drosophila melanogaster for flies (NP_476962.1) and Caenorhabditis 
elegans as a nematode (NP_001033327.1). Multiple sequence alignment was performed 
using Clustl Omega. The candidate mutations are shown in black and the amino acid at that 
position in the different species are shown in red. Any variance that occurs at this position is 
also shown in black.  
(B): All of the missense mutations were predicted to be damaging and pathogenic by 
Polyphen, where most damaging is given a score of 1. These same mutations were also 
predicted to be damaging by SIFT with the lowest score of 0. 
(C): The identified residues are all within in subdomains of the tyrosine kinase 
domain of TRKA as shown.  
 
  
Supplementary Figure S4: Colocalization of TRKA with Na+/K+ ATPase 
 
Colocalization of TRKA at the periphery of the cells with the plasma membrane Na+/K+ 
ATPase was determined in terms of the Manders M1 coefficient. Wild-type TRKA was found 
to colocalize with the plasma membrane as were all the mutant TRKA proteins. WT: wild-
type. 
  
Supplementary Figure S5: Activation of the PLCγ pathway by TRKA mutants 
 
(A): HeLa cells were transfected and the calcium levels were monitored after NGF 
application. Fluorescence at t= 208 s was quantified. The maximum fluorescence in C752S 
transfected cells was not different from the maximum fluorescence of wild-type transfected 
cells. Maximum fluorescence was reduced 2-fold in C763S transfected cells and in all the 
other mutants it did not increase above baseline levels. WT: wild-type. 
(B): The percentage of cells with a calcium response was determined. Any cell that had a 
relative fluorescence greater than 15% of the baseline after NGF addition was classified as a 
responsive cell. A 90% of wild-type and C752S cells had a calcium response, whereas this 
was reduced in C763s transfected cells and was almost 0% in all the other mutants. 
The bar graphs in A and B represent the mean values of n= 3, with around 15 cells in each 
repeat, and error bars represent standard error of the mean. Statistical differences between 
wild-type and mutant TRKA are indicated as **P<0.01 or ***P<0.001 (one-way ANOVA, 
followed by Student’s t test using a Bonferroni adjusted P-value).  
(C): WT transfected HeLa cells were treated with 3 µM of U73122, a phospholipase C 
inhibitor for 30 min. After incubation, the NGF induced increase in fluorescence was 
inhibited. 
  
Supplementary Table S1: Summary of functional characterization of previously identified TRKA 
mutations 
 
Mutation 
Full 
glycosylation 
Membrane 
expression 
Autophos-
phorylation 
Y496 phos-
phorylation 
PLCγ 
activation 
Neurite 
outgrowth 
p.L93P Abolished 
____ 
Abolished Abolished 
____
 
____
 
p.L213P Abolished Null Abolished Abolished 
____
 Abolished 
p.G516R No effect  Abolished Abolished 
____
 
____
 
p.G571R 
____
 No effect Abolished Abolished 
____
 Abolished 
p.R643W No effect 
____
 Abolished Abolished 
____
 Abolished 
p.R648C No effect 
____
 Abolished Abolished 
____
 
____
 
p.G708S No effect 
____
 Abolished Abolished 
____
 Abolished 
p.R774P 
____
 
____
 Abolished 
____
 
____
 
____
 
 
Functional characterization of previously published mutations identified these as functional 
nulls, where kinase activity was abolished. In most cases Y496 phosphorylation was also 
investigated as was the presence of the fully glycosylated form. 
  
Supplementary Table S2: Summary of phenotype of patients 
 
Nucleotide numbering uses +1 as the A of the ATG translation imitation codon in the reference sequence, with the initiation codon as 
codon 1 (RefSeq ID NM_002529.3, NP_002520) . 
Case NTRK1 mutations 
TRKA 
protein 
Age at 
diagnosis 
Ethnicity 
and sex 
Congeital 
analgaesia 
Sweating 
Temperature 
sensing/ episodes 
of hyperthermia 
Itching/ and 
licheni-
fication 
Cognition 
Staphylococcal 
Aureus infections/ 
Charcot’s joints 
1 
Het c.1550G>A, 
c.717+4A>T
a
 
p.G517E, 
Null 
15y 
Caucasian, 
male 
Yes None None/No No/No 
Mild cognitive 
delay 
Yes/yes 
2 
Het c.1565G>A, 
c.2254T>A 
p.G522E, 
p.C752S 
8y 
Caucasian, 
female 
Yes None None/No Yes/No 
Mild cognitive 
delay 
Yes/ No 
3 and 
4 
Homozygous 
c.1970T>C 
p.L657P 
10y and 
3y 
Pakistani*, 
female and 
male 
Yes None None/No 
Yes/Yes and 
Yes/No 
Moderate 
cognitive 
delay and ? 
Yes/Yes and 
Yes/No 
5 
Het c.2096T>C, 
c.287+2 dupT
b
 
p.I699T, 
Null 
3y 
Pakistani, 
male 
Yes None None/Yes Yes/No 
Mild cognitive 
delay 
Yes/No 
6 
Homozygous 
c.2288G>C 
p.C763S 6y 
Turkish*, 
Male 
Yes None None/Yes Yes/No 
Mild cognitive 
delay 
Yes/No 
7 
Homozygous 
c.2311C>T 
R771C 8y 
Indian*, 
male 
Yes None None/Yes Yes/Yes 
Moderate 
cognitive 
delay 
Yes/No 
a. Alters an evolutionary conserved splice donor site of intron 6 from gGTAAT to gGTATT, where the +4 A is conserved in all species with a NTRK1 
gene. Of note the spice acceptor for this intron 5 of NTRK1 is predicted as poor TAACACCCCTTGGCCCTCGGCGTCCTGGGTGGCCAGg. MIT splice 
predictor, SplicePort and NetGene2 – do not predict the proven NTRK1 intron 5 acceptor splice site.  
b. Changing the splice donor site from tGTGAG to tGTTGAG; previously reported as pathogenic in Lee ST et al, Muscle Nerve, 2009, 40(5):855-9)  
*.  Parents consanguineous. 
 
